冠心病患者血浆脂蛋白(a)与载脂蛋白水平检测分析  

Analysis on Lipoprotein a and Apolipoproteins in Coronary Artery Disease Individual

作　　者：杨刚[1] 杨桂[1] 胡汉宁[1] 陈薇[1] 吕民[1] 

机构地区：[1]武汉大学中南医院检验科,邮政编码武汉430071

出　　处：《微循环学杂志》2005年第4期54-56,共3页Chinese Journal of Microcirculation

摘　　要：目的观察脂蛋白(a)与冠心病发展病程之间的关系。方法将冠心病患者498例按病程发展的各期进行分组。以免疫透射比浊法对冠心病患者各组血浆中脂蛋白(a)、载脂蛋白A1、载脂蛋白B水平进行检测。结果冠心病患者血中Lp(a)、ApoB水平明显高于健康对照组(P<0.05)。随着冠状动脉粥样硬化的严重程度逐步增加,血中Lp(a)、ApoB逐步上升,与病程呈正相关关系(r=0.4596,P<0.05)。结论Lp(a)与冠心病病程发展有着密切的联系。检测血中Lp(a)浓度对预防冠状动脉栓塞的发生和发展具有临床指导意义和应用价值。Objective: Observe the relationship between lipoprotein a and progress of coronary artery disease.Method: Group 498 CHD patients by staging of CHD development. Detect the levels of lipoprotein a, apolipoprotein B and apolipoprotein A1 in plasma of CHD patients by immunoturbidimetric assay. Results: The levels of lipoprotein a and apolipoprotein B in plasma of patients with CHD were slightly higher than health subjects(P<0.05).The level of lipoprotein a and apolipoprotein B in plasma rise gradually with the increasing of the severity degree of coronary atherosclerosis,and are positive correlated with the course of CHD(r=0.4596,P<0.05). Conclusion: Lipoprotein a is closely associated with the development of CHD. Detection of lipoprotein a in plasma has directional clinical significance and application value in precluding the occurring and development of the coronary artery embolization.

关 键 词：血浆脂蛋白(a) 冠心病患者 检测分析 蛋白水平 血浆Lp(a) 动脉粥样硬化 武汉大学中南医院 载脂蛋白B 低密度脂蛋白 前瞻性研究 

分 类 号：R582.1[医药卫生—内分泌] R541.4[医药卫生—内科学]